Department of Oncology, Qingdao Municipal Hospital, Qingdao, China.
Department of Internal Medicine, Linyi Cancer Hospital, Linyi, China.
Clin Transl Sci. 2021 Jan;14(1):389-394. doi: 10.1111/cts.12891. Epub 2020 Oct 22.
The aim of this study was to determine the expression of IL-35 and the lymphatic vessel density (LVD) and microvessel density (MVD) in the pathological tissues from patients with non-small cell lung cancer (NSCLC) and to analyze their correlation with other common clinical prognostic factors, as well as patients' overall survival and progression-free survival. We analyzed the pathological characteristics of 130 patients with NSCLC and determined the IL-35 expression, MVD, and LVD changes in the pathological tissues by immunohistochemistry. The results showed that IL-35 expression was significantly correlated with tumor differentiation, lymph node metastasis, T staging, LVD, and MVD (P < 0.05) but was not associated with age, sex, smoking, and other factors. Univariate analysis of risk models showed that age, lymph node metastasis, T stage, and high IL-35 expression, LVD, and MVD were significantly associated with NSCLC prognosis (P < 0.05), whereas sex, smoking, and high differentiation were not correlated with prognosis. Multivariate analysis of the proportional risk model showed that the IL-35 expression, lymph node metastasis, high LVD, and high MVD were significantly correlated with NSCLC prognosis (P < 0.05). In conclusion, IL-35, MVD, and LVD may be independent prognostic markers. In addition, IL-35 might represent a promising clinical drug target for the treatment of NSCLC.
本研究旨在确定白细胞介素 35(IL-35)在非小细胞肺癌(NSCLC)患者病理组织中的表达,并分析其与其他常见临床预后因素以及患者总生存期和无进展生存期的相关性。我们分析了 130 例 NSCLC 患者的病理特征,通过免疫组织化学方法确定了病理组织中 IL-35 表达、MVD 和 LVD 的变化。结果表明,IL-35 表达与肿瘤分化、淋巴结转移、T 分期、LVD 和 MVD 显著相关(P<0.05),但与年龄、性别、吸烟等因素无关。风险模型的单因素分析显示,年龄、淋巴结转移、T 分期和高 IL-35 表达、LVD 和 MVD 与 NSCLC 预后显著相关(P<0.05),而性别、吸烟和高分化与预后无关。比例风险模型的多因素分析显示,IL-35 表达、淋巴结转移、高 LVD 和高 MVD 与 NSCLC 预后显著相关(P<0.05)。总之,IL-35、MVD 和 LVD 可能是独立的预后标志物。此外,IL-35 可能成为治疗 NSCLC 的有前途的临床药物靶点。